AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Leukemia Unknown Primary	NCT ID:	NCT06137118
Trial Phases:	Phase I Phase II	Protocol IDs:	D7405C00001 (primary) NCI-2023-11025 2018-002011-10
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06137118

Summary

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose
optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and
efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study
will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose
optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization
and efficacy expansion in R/R B-ALL (2L+)

Objectives

This dose escalation and optimization study is evaluating the safety, tolerability, PK,
PD and clinical activity of surovatamig (AZD0486) monotherapy in r/r B-ALL.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.